The guidelines recommend offering preventive therapy to adults who experience 4 or more migraine days per month or significant migraine-related disability, emphasizing shared decision-making based on patient preferences, comorbidities, and treatment goals. Newer CGRP-targeted therapies are now incorporated alongside established options, with treatment selection guided by the strength of evidence, safety profile, and route of administration. The guidelines also provide recommendations for both episodic and chronic migraine and include guidance on evaluating treatment effectiveness and ongoing management.